{
    "clinical_study": {
        "@rank": "29992", 
        "arm_group": {
            "arm_group_label": "Ir-192 high dose rate (HDR)", 
            "arm_group_type": "Experimental", 
            "description": "This pilot study is an investigation into the use of Ir-192 high dose rate (HDR) afterloader-based brachytherapy with catheter placement using image-guided surgical navigation techniques for patients with painful/symptomatic metastatic or recurrent lesions in the spine that have been maximally treated with external beam radiation therapy."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if using a form of imaging during surgery helps the\n      doctors to guide the placement of radiation catheters more accurately.\n\n      This method, called \"image-guided surgical navigation\" may allow the doctors to deliver the\n      radiation to the spinal tumor that you need and decrease the amount of radiation delivered\n      to the spinal cord."
        }, 
        "brief_title": "Image-Guided Navigation for High Dose Rate Temporary Interstitial Brachytherapy in the Palliative Management of Previously Treated Tumors of the Spine", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic or Recurrent Lesions in the Spine", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have histologic proof of a malignancy suitable for radiation therapy.\n\n          -  Patients must have received prior external beam radiation therapy to the region\n             proposed for HDR brachytherapy treatment; evaluation of doses previously delivered to\n             spinal cord/cauda equina and other critical structures (bowel, kidneys, rectum) will\n             be taken into consideration.\n\n          -  If repeat irradiation would exceed any normal tissue constraint set by MSKCC\n             Radiation Oncology Department dose constraint criteria, the patient will potentially\n             be eligible.\n\n          -  If the total prior radiation dose to the cord exceeds 100 Gy in 2 Gy BED equivalents,\n             the patient will be potentially eligible, where a total of 100 Gy in 2 Gy equivalents\n             is determined by the biological equivalent dose (BED) calculation; BED(2Gy\n             equivalents) = nd(1 + d/\u03b1/\u03b2), where n = number of fractions and d = dose per\n             fraction; \u03b1/\u03b2 is the constant for spinal cord late effect and equals 2. [Rades 2005,\n             Nieder 2005, Sahgal 2012]\n\n          -  KPS \u2265 60\n\n          -  Age \u2265 18 years old\n\n        Exclusion Criteria:\n\n          -  Patients who may receive therapeutically effective doses via an external beam\n             approach to the lesion of interest as specified by MSKCC Radiation Oncology\n             Department dose constraint criteria.\n\n          -  Patients with kyphoplasty cement or hardware that would preclude effective catheter\n             placement.\n\n          -  Patients with paraspinal extension of disease with visceral involvement.\n\n          -  Abnormal complete blood count. Any of the following:\n\n          -  Platelet count < 75,000/ml\n\n          -  Hb level < 9gm/dl\n\n          -  WBC < 3.5/ml\n\n          -  Abnormal coagulation profile: INR > 2.5 and/or PTT > 80\n\n          -  Patients who are on anticoagulation medication that may not be safely held for the\n             procedure (\u2265 5 days for antiplatelet agents and warfarin; \u2265 24 hours for\n             low-molecular weight heparin formulations) will be excluded.\n\n          -  Contraindications to general anesthesia"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01757717", 
            "org_study_id": "12-260"
        }, 
        "intervention": {
            "arm_group_label": "Ir-192 high dose rate (HDR)", 
            "description": "Patients will be followed at 2 months (+/- 2 weeks) post-treatment and then approximately every 3 months (+/- 2 weeks) until approximately 11 months of follow up. They will be evaluated for pain referable to the treated site, clinical and radiographic evidence of local progression, and treatment related toxicity. Thereafter, patients will be followed as clinically indicated.", 
            "intervention_name": "Ir-192 high dose rate (HDR)", 
            "intervention_type": "Radiation"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "radiation therapy", 
            "HDR brachytherapy", 
            "Ir-192 high dose rate", 
            "12-260"
        ], 
        "lastchanged_date": "December 9, 2013", 
        "link": {
            "description": "Memorial Sloan-Kettering Cancer Center", 
            "url": "http://www.mskcc.org/"
        }, 
        "location": {
            "contact": {
                "last_name": "Yoshiya Yamada, MD", 
                "phone": "212-639-2950"
            }, 
            "contact_backup": {
                "last_name": "Mark Bilsky, MD", 
                "phone": "212-639-8526"
            }, 
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10065"
                }, 
                "name": "Memorial Sloan Kettering Cancer Center"
            }, 
            "investigator": {
                "last_name": "Yoshiya Yamada, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Pilot Study of Image-Guided Navigation for High Dose Rate Temporary Interstitial Brachytherapy in the Palliative Management of Previously Treated Tumors of the Spine", 
        "overall_contact": {
            "last_name": "Yoshiya Yamada, MD", 
            "phone": "212-639-2950"
        }, 
        "overall_contact_backup": {
            "last_name": "Mark Bilsky, MD", 
            "phone": "212-639-8526"
        }, 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Yoshiya Yamada, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "of spine lesions using catheters placed under image guided navigational techniques, to provide improved dosimetric coverage of spinal lesions such that.\nIn terms of technical feasibility, a patient is regarded as being successfully treated if the target D90 is \u2265 80% AND the cord/cauda max dose is 8 Gy.", 
            "measure": "feasibility of High Dose Rate (HDR) treatment", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01757717"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "for previously irradiated lesions of the spine, defined as an acceptable level of severe toxicity (both acute and late effects) in the setting of HDR brachytherapy treatment. Severe toxicity will be defined as \u2265 grade 3 NCI CTCAE v 4.0 toxicity that is at least possibly related to treatment", 
            "measure": "Toxicity of HDR brachytherapy", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}